Filing Details

Accession Number:
0001209191-23-056354
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-21 18:00:14
Reporting Period:
2023-11-17
Accepted Time:
2023-11-21 18:00:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1816160 James Kihara C/O Acadia Pharmaceuticals, Inc.
12830 El Camino Real, Suite 400
San Diego CA 92130
Principal Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-17 1,982 $0.00 13,028 No 4 M Direct
Common Stock Acquisiton 2023-11-17 1,982 $0.00 15,010 No 4 M Direct
Common Stock Disposition 2023-11-20 1,985 $22.64 13,025 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-11-17 1,982 $0.00 1,982 $0.00
Common Stock Restricted Stock Units Disposition 2023-11-17 1,982 $0.00 1,982 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,931 No 4 M Direct
7,931 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  2. Includes 268 shares of the Issuer's common stock acquired by the reporting person on November 15, 2023 pursuant to an employee stock purchase program.
  3. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.615 to $22.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
  6. The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.